Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

UFPT vs HAE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HAE Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–4 Matrix Metrics)

HAE Overall Winner 6-Pillar Tally: UFPT 1 – 4 HAE (1 Tie) Matrix Metrics: UFPT 4 – 6 HAE

As of Nov 16, 2026, Haemonetics Corporation (HAE) is the stronger overall head-to-head candidate over UFP Technologies Inc (UFPT) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). UFPT carries a Unified Composite Score of 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin), whereas HAE carries 51.4/100 (HOLD) at $121.34 (22.9x Forward P/E, 18.8% operating margin).

  • Technical & Structure Timing Caution: UFPT is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8); meanwhile HAE trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 59.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About UFPT vs HAE
UFPT NASDAQ
UFP Technologies Inc
Surgical & Medical Instruments & Apparatus
$298.54
-2.14% 1D
Market Cap $2.4B
TTM Revenue $650M
Forward P/E 24.7x
Beta / 30D Vol 1.64β · 77% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 25.0 Fund 37.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -1.1%) with fading momentum, RSI 50
RSI-14: 49.8 · SMA20: $298.97 · SMA50: $293.17
HAE NYSE Head-to-Head Winner
Haemonetics Corporation
Surgical & Medical Instruments & Apparatus
$121.34
-1.3% 1D
Market Cap $5.6B
TTM Revenue $1.38B
Forward P/E 22.9x
Beta / 30D Vol 0.27β · 32% Vol
Unified Composite Score
51.4 / 100 HOLD
Tech 53.0 Fund 47.0 Flow 50.0 Mom 36.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.5% over 20 days), RSI 59
RSI-14: 59.0 · SMA20: $120.43 · SMA50: $113.71

6-Pillar Scorecard Institutional Category Breakdown (UFPT 1 – 4 HAE)

Columns: Metric · UFPT · HAE
1. Valuation Multiples HAE
Forward P/E 24.7x 22.9x
Trailing P/E 31.2x 54.4x
PEG Ratio 3.80x 1.92x
EV / Revenue 3.6x 4.0x
2. Growth & Scale UFPT
Revenue Growth (YoY) +11.6% +9.3%
Earnings Growth (YoY) +25.1% +23.5%
TTM Revenue (USD) $650M $1.38B
Market Cap $2.4B $5.6B
3. Profitability & Quality HAE
Gross Margin 28.9% 59.8%
Operating Margin 15.4% 18.8%
Net Profit Margin 11.8% 7.5%
Return on Equity (ROE) 17.2% 11.9%
4. Balance Sheet & Cash Flow HAE
Cash Generation (TTM) $120M EBITDA $364M EBITDA
Cash Flow Margin 18.5% EBITDA Mgn 26.3% EBITDA Mgn
Net Cash / Leverage $62.70 Book/Sh · 17.2% ROE $19.74 Book/Sh · 11.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 42.3% (3rd %ile) 32.7% (2nd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Markup
6. R&D & Supply-Chain Moat HAE
OpEx & R&D Intensity 13.5% of Rev ($88M) 41.0% of Rev ($567M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Scale & Operating Efficiency Moat
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: UFPT (4) vs HAE (6)
Institutional Metric UFPT HAE Criterion Row Edge
Market Capitalization
Scale
$2.4B $5.6B Larger Scale HAE
Trailing P/E Ratio
Valuation
31.2x 54.4x Lower Multiple UFPT
Forward P/E Ratio
Valuation
24.7x 22.9x Lower Multiple HAE
Revenue Growth (YoY)
Growth
+11.6% +9.3% Higher Growth UFPT
Operating Margin (TTM)
Profitability
15.4% 18.8% Higher Margin HAE
Net Profit Margin
Profitability
11.8% 7.5% Higher Margin UFPT
Return on Equity (ROE)
Capital Efficiency
17.2% 11.9% Higher ROE UFPT
52-Week Range Position
Momentum
74% ($174–$342) 87% ($51–$132) Stronger Trend HAE
Beta / 30D Volatility
Risk Regime
1.64β · 77% Vol 0.27β · 32% Vol Lower Realized Risk HAE
Unified Institutional Score
Composite Signal
42.6 / 100 (HOLD) 51.4 / 100 (HOLD) Higher Composite HAE
Trailing 12M Revenue (USD)
Operating Scale
$650M $1.38B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
28.9% 59.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.80x PEG · 3.6x EV/Rev 1.92x PEG · 4.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$120M EBITDA ($62.70 Book/Sh · 17.2% ROE) $364M EBITDA ($19.74 Book/Sh · 11.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HAE +0.23 pp
UFPT: +2.36% · HAE: +2.59%
3M Horizon HAE +20.87 pp
UFPT: -4.92% · HAE: +15.95%
6M Horizon HAE +74.4 pp
UFPT: +37.44% · HAE: +111.84%
1Y Horizon HAE +36.75 pp
UFPT: +27.42% · HAE: +64.17%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on UFPT vs HAE. Trailing 12-month operating profitability (UFPT 15.4% vs HAE 18.8%) and valuation multiples (UFPT 24.7x vs HAE 22.9x Forward P/E) are benchmarked directly in Pillar 4 below.

UFPT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$650M
Gross Margin28.9%
Op. Margin15.4%
ROE / Fwd P/E17.2% · 24.7x
HAE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.38B
Gross Margin59.8%
Op. Margin18.8%
ROE / Fwd P/E11.9% · 22.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
UFPT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 42.3%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UFPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
HAE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 32.7%
IV Percentile 2nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HAE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
UFPT Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $2.4B market capitalization and 15.4% operating margin.
OpEx & R&D Reinvestment 13.5% of Rev ($88M)
90D Engineering Disclosures 0 Published
HAE Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $5.6B market capitalization and 18.8% operating margin.
OpEx & R&D Reinvestment 41.0% of Rev ($567M)
90D Engineering Disclosures 0 Published

Investor FAQ UFPT vs HAE Key Questions & Quantitative Answers

As of Nov 16, 2026, Haemonetics Corporation (HAE) is the stronger overall head-to-head candidate over UFP Technologies Inc (UFPT) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). UFPT carries a Unified Composite Score of 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin), whereas HAE carries 51.4/100 (HOLD) at $121.34 (22.9x Forward P/E, 18.8% operating margin). Technical & Structure Timing Caution: UFPT is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8); meanwhile HAE trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 59.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

UFPT leads the Growth & Scale pillar: UFPT posts +11.6% YoY revenue growth and +25.1% YoY earnings growth on $650M TTM revenue (28.9% gross margin, 15.4% operating margin), compared with HAE at +9.3% YoY revenue growth and +23.5% YoY earnings growth on $1.38B TTM revenue (59.8% gross margin, 18.8% operating margin). On trailing 12-month operating scale, UFPT generates $650M in USD-normalized revenue versus $1.38B for HAE. In operating R&D and SG&A reinvestment, UFPT deploys 13.5% of Rev ($88M) (0 90-day corporate R&D disclosures) versus 41.0% of Rev ($567M) (0 disclosures) for HAE.

HAE screens cheaper on headline valuation multiples. UFPT trades at 24.7x Forward P/E, 31.2x Trailing P/E, 3.80x PEG, and 3.6x EV/Revenue (18.5% EBITDA margin), whereas HAE trades at 22.9x Forward P/E, 54.4x Trailing P/E, 1.92x PEG, and 4.0x EV/Revenue (26.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against UFPT (17.2% ROE) versus HAE (11.9% ROE) capital efficiency.

In options market volatility and institutional positioning, UFPT carries 42.3% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.64β · 77% Vol realized risk). By comparison, HAE carries 32.7% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.27β · 32% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.